Concepedia

Kyle Parcella

KP

7

Publications

129

Citations

7

H-Index

2017

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Kyle Parcella is an author at Bristol-Myers Squibb (United States) specializing in medicinal chemistry, drug discovery, and hepatitis c.

ORCID

Top concepts

Publications per year

2017–2023

7

Publications

7

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies

Kap‐Sun Yeung, Brett R. Beno, Kyle Parcella et al. · Journal of Medicinal Chemistry · 2017 · 31 citations · Full text

, , +17

Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor

Kyle Parcella, Kyle J. Eastman, Kap‐Sun Yeung et al. · ACS Medicinal Chemistry Letters · 2017 · 25 citations · Full text

Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold

Eric P. Gillis, Kyle Parcella, Michael Bowsher et al. · Journal of Medicinal Chemistry · 2023 · 22 citations

The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase

Kyle J. Eastman, Kyle Parcella, Kap‐Sun Yeung et al. · MedChemComm · 2017 · 18 citations · Full text

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor

Kyle Parcella, Tao Wang, Kyle J. Eastman et al. · ACS Medicinal Chemistry Letters · 2022 · 12 citations · Full text

Rows per page

1–5 of 7